Aura Biosciences Inc (AURA) Reports Q1 2024 Earnings: A Detailed Financial Overview
Scotiabank Remains a Buy on Aura Biosciences Inc (AURA)
Aura Biosciences: A Strong Buy on Promising Clinical Trials and Market Potential
Aura Biosciences: A Strong Buy on Promising Cancer Treatments and Solid Financials
Aura Biosciences Reports Q1 Results
Aura Biosciences | 10-Q: Quarterly report
Aura Biosciences 1Q Loss/Shr 40c >AURA
Aura Biosciences 1Q Loss/Shr 40c >AURA
Press Release: Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights
Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoi
Raj Parekh to Exit Board at Aura Biosciences' Meeting
Aura Biosciences Inc: A Buy Rating on Strong Pipeline and Financial Health
Analysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF), Molina Healthcare (MOH) and Aura Biosciences Inc (AURA)
Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Spectral AI (MDAI) and Pyxis Oncology (PYXS)
We're Not Very Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn Rate
Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Altimmune (ALT)
Aura Biosciences Shares Rise Following Q4 Results
Aura Biosciences (AURA) shares were up more than 2% in recent Wednesday trading after the clinical-stage biotechnology company reported its Q4 results. Earlier, the company booked a Q4 net loss of $22
Aura Biosciences GAAP EPS of -$1.93
Aura Biosciences: A Strong Buy on Clinical Progress and Financial Stability
Recap: Aura Biosciences Q4 Earnings
Aura Biosciences (NASDAQ:AURA) reported its Q4 earnings results on Wednesday, March 27, 2024 at 07:00 AM.Here's what investors need to know about the announcement.EarningsAura Biosciences beat estimat
Aura Biosciences Inc Files For Mixed Shelf Offering Of Up To $350M
Aura Biosciences Inc Files For Mixed Shelf Offering Of Up To $350M
Aura Biosciences FY 2023 EPS $(1.93) Misses $(1.82) Estimate
Aura Biosciences (NASDAQ:AURA) reported quarterly losses of $(1.93) per share which missed the analyst consensus estimate of $(1.82) by 6.04 percent. This is a 1.53 percent increase over losses of $(1
No Data